Federico Paoletti

Federico Paoletti has a diverse work experience spanning multiple sectors. Starting in 2014, they worked as a PhD candidate at the University of Oxford, focusing on DNA repair and its role in cancer development. In 2016, they participated in the Global Health Challenge at EIT Health. Federico then worked as a researcher for Polygeia, specifically in responding to cholera outbreaks. From 2017 to 2018, they served as a lead data consultant for Evidence Aid, specializing in evidence synthesis. In 2018, Federico participated in the UK Insight Programme at McKinsey & Company. Federico later interned at the World Health Organization, specifically in the surveillance of noncommunicable diseases. In 2019, Federico co-founded and became CEO of Exogene Ltd. Federico also participated in the Entrepreneur First program as part of the LD13 Cohort and was a cohort member in the Creative Destruction Lab's Health Stream. In 2021, they became a cohort member at KQ Labs.

Federico Paoletti pursued their education in a systematic manner. Federico started their academic journey in 2011 at the University of York, where they completed their Bachelor of Science (BSc) degree in Genetics in 2014. Following this, they went on to join the University of Oxford in 2014 to pursue a Ph.D. in Molecular and Computational Oncology. Federico successfully completed their doctoral studies in 2018.

In addition to their formal education, Federico Paoletti also obtained a certification in Drug Discovery. This certification was obtained in August 2019 from the institution Coursera.